Acrivon Therapeutics (NASDAQ:ACRV) versus Oasmia Pharmaceutical (OTCMKTS:OASMY) Financial Comparison

Oasmia Pharmaceutical (OTCMKTS:OASMY) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Institutional & Insider Ownership

71.6% of Acrivon Therapeutics shares are held by institutional investors. 11.9% of Acrivon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Oasmia Pharmaceutical and Acrivon Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oasmia Pharmaceutical	N/A	N/A	N/A
Acrivon Therapeutics	N/A	-57.23%	-51.09%

Analyst Ratings

This is a breakdown of recent recommendations for Oasmia Pharmaceutical and Acrivon Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oasmia Pharmaceutical	0	0	0	0	0.00
Acrivon Therapeutics	1	1	4	0	2.50

Acrivon Therapeutics has a consensus price target of $11.67, suggesting a potential upside of 667.54%. Given Acrivon Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Acrivon Therapeutics is more favorable than Oasmia Pharmaceutical.

Earnings and Valuation

This table compares Oasmia Pharmaceutical and Acrivon Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oasmia Pharmaceutical	N/A	N/A	N/A	N/A	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90 million	($2.02)	-0.75

Summary

Acrivon Therapeutics beats Oasmia Pharmaceutical on 5 of the 7 factors compared between the two stocks.

About Oasmia Pharmaceutical

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.